Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
643 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01511913 | A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma(IMAGE) | completed | — | 1,411 | Bristol-Myers SquibbINDUSTRY | 15 | Dec 28, 2021 | clinicaltrials |
| NCT02857426 | A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)(CheckMate 647) | completed | Phase 2 | 66 | Bristol-Myers SquibbINDUSTRY |
| 13 |
| Dec 23, 2021 |
| clinicaltrials |
| NCT05168436 | A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal | completed | — | 105 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 23, 2021 | clinicaltrials |
| NCT02856646 | Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices | completed | — | 290 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 15, 2021 | clinicaltrials |
| NCT01460160 | Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia | completed | Phase 2 | 106 | Bristol-Myers SquibbINDUSTRY | 6 | Dec 8, 2021 | clinicaltrials |
| NCT00730639 | A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies(MDX1106-03) | completed | Phase 1 | 395 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 3, 2021 | clinicaltrials |
| NCT01472081 | Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) | completed | Phase 1 | 194 | Bristol-Myers SquibbINDUSTRY | 2 | Dec 2, 2021 | clinicaltrials |
| NCT03126617 | Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 0 | Nov 29, 2021 | clinicaltrials |
| NCT03126643 | Expanded Access to Nivolumab (Opdivo) | approved for marketing | — | — | Bristol-Myers SquibbINDUSTRY | 0 | Nov 29, 2021 | clinicaltrials |
| NCT05123950 | A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe | completed | — | 304 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 17, 2021 | clinicaltrials |
| NCT03661632 | An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 27 | Bristol-Myers SquibbINDUSTRY | 3 | Nov 8, 2021 | clinicaltrials |
| NCT01358721 | Phase I Biomarker Study (BMS-936558) | completed | Phase 1 | 119 | Bristol-Myers SquibbINDUSTRY | 3 | Oct 28, 2021 | clinicaltrials |
| NCT02038933 | Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) | completed | Phase 2 | 121 | Bristol-Myers SquibbINDUSTRY | 12 | Oct 14, 2021 | clinicaltrials |
| NCT02320058 | An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself(CheckMate204) | completed | Phase 2 | 119 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 5, 2021 | clinicaltrials |
| NCT03745807 | An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors | completed | Phase 1 | 3 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 4, 2021 | clinicaltrials |
| NCT00112580 | MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 27 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 27, 2021 | clinicaltrials |
| NCT03068455 | An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma(CheckMate 915) | completed | Phase 3 | 1,844 | Bristol-Myers SquibbINDUSTRY | 19 | Sep 20, 2021 | clinicaltrials |
| NCT02305563 | An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 70 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 16, 2021 | clinicaltrials |
| NCT03505515 | Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer | completed | — | 6,205 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 14, 2021 | clinicaltrials |
| NCT01783938 | Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) | completed | Phase 2 | 138 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 13, 2021 | clinicaltrials |
| NCT03349710 | Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer | completed | Phase 3 | 74 | Bristol-Myers SquibbINDUSTRY | 10 | Aug 9, 2021 | clinicaltrials |
| NCT03098550 | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread | completed | Phase 1 / Phase 2 | 105 | Bristol-Myers SquibbINDUSTRY | 9 | Jul 23, 2021 | clinicaltrials |
| NCT03329846 | An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma | completed | Phase 3 | 20 | Bristol-Myers SquibbINDUSTRY | 16 | Jul 9, 2021 | clinicaltrials |
| NCT01891643 | PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy) | terminated | Phase 3 | 23 | Bristol-Myers SquibbINDUSTRY | 4 | Jul 1, 2021 | clinicaltrials |
| NCT02599402 | Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma(CheckMate 401) | completed | Phase 3 | 533 | Bristol-Myers SquibbINDUSTRY | 12 | Jun 15, 2021 | clinicaltrials |
| NCT00971945 | Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer | completed | Phase 2 | 6 | Bristol-Myers SquibbINDUSTRY | 1 | May 25, 2021 | clinicaltrials |
| NCT02574078 | A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)(CheckMate370) | completed | Phase 1 / Phase 2 | 341 | Bristol-Myers SquibbINDUSTRY | 1 | May 6, 2021 | clinicaltrials |
| NCT02750514 | An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer(FRACTION-Lung) | terminated | Phase 2 | 295 | Bristol-Myers SquibbINDUSTRY | 8 | Mar 22, 2021 | clinicaltrials |
| NCT04495010 | Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants(CheckMate 7UA) | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 16 | Mar 19, 2021 | clinicaltrials |
| NCT00306202 | Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia | completed | Phase 1 | 63 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 26, 2021 | clinicaltrials |
| NCT03158272 | A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread | completed | Phase 1 | 19 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT03363776 | An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers | terminated | Phase 1 / Phase 2 | 10 | Bristol-Myers SquibbINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT02905266 | A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma | completed | Phase 3 | 106 | Bristol-Myers SquibbINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT03444766 | Study of Nivolumab for Advanced Cancers in India | completed | Phase 4 | 100 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT02475382 | Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen(CheckMate 169) | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 2 | Nov 27, 2020 | clinicaltrials |
| NCT02253992 | An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 232 | Bristol-Myers SquibbINDUSTRY | 4 | Oct 5, 2020 | clinicaltrials |
| NCT03450876 | Long Term Quality of Life in Melanoma Patients in Netherlands | completed | — | 89 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 11, 2020 | clinicaltrials |
| NCT03351231 | An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer | terminated | Phase 1 / Phase 2 | 7 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 26, 2020 | clinicaltrials |
| NCT01225172 | Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors | terminated | Phase 2 | 77 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 11, 2020 | clinicaltrials |
| NCT01611558 | Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer | completed | Phase 2 | 40 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 13, 2020 | clinicaltrials |
| NCT01450761 | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | completed | Phase 3 | 1,351 | Bristol-Myers SquibbINDUSTRY | 34 | Jul 8, 2020 | clinicaltrials |
| NCT01285609 | Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin | completed | Phase 3 | 1,289 | Bristol-Myers SquibbINDUSTRY | 36 | Jun 18, 2020 | clinicaltrials |
| NCT02545075 | A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine | completed | Phase 3 | 182 | Bristol-Myers SquibbINDUSTRY | 1 | May 19, 2020 | clinicaltrials |
| NCT02534506 | Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors | completed | Phase 1 | 18 | Bristol-Myers SquibbINDUSTRY | 1 | May 18, 2020 | clinicaltrials |
| NCT02516527 | A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors | completed | Phase 1 | 25 | Bristol-Myers SquibbINDUSTRY | 1 | May 1, 2020 | clinicaltrials |
| NCT03769558 | A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur | completed | — | 264 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 20, 2020 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials